Business Context and Reporting Period
Company: SciSparc Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: August 2024 (Report No. 4)
Date Filed: August 19, 2024
Principal Executive Offices: Tel Aviv, Israel
This filing reports a material corporate transaction involving the out-licensing of the Company's SCI-160 program (pain therapy assets) and the termination of a prior co-development agreement.
Key Financial Metrics
The filing does not provide standard financial statements (revenue, profit, cash flow, margins, debt, or liquidity) for the period. The only specific financial value disclosed relates to the transaction consideration:
- Transaction Consideration: The Company will receive shares in Polyrizon Ltd. reflecting an issue price of $3 million.
- Future Revenue Streams: The agreement includes royalties from sales/income generated from the assets and pre-determined fees upon completion of development milestones.
Material Changes
On August 13, 2024, SciSparc Ltd. executed two significant agreements with Polyrizon Ltd.:
- Exclusive Patent License Agreement: SciSparc granted Polyrizon an exclusive, royalty-bearing, sub-licensable license for the SCI-160 program.
- Termination of Co-Development Agreement: The parties terminated a co-development agreement originally dated May 30, 2022.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release on August 16, 2024, announcing the finalization of the exclusive global out-licensing agreement for its pain therapy program.
Forward-Looking Statements: The filing incorporates by reference a press release containing forward-looking statements subject to cautionary risks. These statements are not guaranteed and are subject to uncertainties.
Risks and Contingencies: Future financial benefits are contingent upon the Licensee achieving specific development milestones and generating sales income to trigger royalty payments. The filing does not detail specific operational risks beyond the standard cautionary language regarding forward-looking statements.
Investor Verification Checklist
- Verify the valuation and liquidity of the Polyrizon Ltd. shares received as consideration ($3 million issue price).
- Review the specific development milestones required to trigger pre-determined fees.
- Examine the royalty rate structure and sales thresholds defined in the License Agreement (Exhibit 10.1).
- Confirm the terms of the terminated co-development agreement to understand any potential liabilities or obligations released.
- Assess the impact of this out-licensing on SciSparc's future revenue model and cash flow projections.